Delcath Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCTH research report →
About the company
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver.
- CEO
- Gerard J. Michel
- IPO
- 2018
- Employees
- 96
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $455.69M
- P/E
- 825.00
- P/S
- 5.04
- P/B
- 4.22
- EV/EBITDA
- 248.97
- Div Yield
- 0.00%
- Gross Margin
- 85.97%
- Op Margin
- -1.79%
- Net Margin
- 0.62%
- ROE
- 0.51%
- ROIC
- -0.59%
- Revenue
- $85.23M · 129.08%
- Net Income
- $2.70M · 110.23%
- EPS
- $-0.05 · 50.94%
- Op Income
- $660.00K
- FCF YoY
- 208.99%
- 52W High
- $13.44
- 52W Low
- $8.12
- 50D MA
- $11.36
- 200D MA
- $10.31
- Beta
- 0.49
- Avg Volume
- 463.88K
Get TickerSpark's AI analysis on DCTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Sylvester John Richard | other | 22,500 |
| May 13, 26 | Martell Bridget A | other | 22,500 |
| May 13, 26 | CZEREPAK ELIZABETH | other | 22,500 |
| May 13, 26 | SALAMON STEVEN A J | other | 22,500 |
| May 13, 26 | Aharon Gil | other | 22,500 |
| Mar 6, 26 | Pennell Sandra | buy | 5,533 |
| Mar 2, 26 | MICHEL GERARD J | buy | 11,200 |
| Feb 17, 26 | Hoffman David L. | other | 56,500 |
| Feb 17, 26 | Hoffman David L. | other | 28,250 |
| Feb 17, 26 | Muir Kevin | other | 56,500 |
Our DCTH coverage
Recent articles, reports, and earnings notes.
No research on DCTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCTH report →Similar companies
Peers in the same neighborhood.